Do peptide inhibitors of MK2 show promise for inhibition of abdominal adhesions?
In conclusion, the peptide inhibitor of MK2, MMI-0100, has the potential to significantly reduce inflammation through suppression of inflammatory cytokine expression and showed promise as a therapeutic for abdominal adhesions.
T1SE, but not T1IR, should be used as T1-weighted imaging in detecting brain metastases, because T1SE imaging has a greater sensitivity than T1IR imaging both before and after contrast material administration.